How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency
While mitapivat addresses the previously unmet needs of most patients with PK deficiency as the first and only disease-modifying medication to receive approval for this condition, not all patients with PK deficiency are amenable to treatment with mitapivat.
Authors
- Chakra P. Chaulagain (ORCID: https://orcid.org/0000-0002-4641-2217)
- Ludovic Saba (ORCID: https://orcid.org/0000-0002-2743-674X)
- Sara Tama-Shekan
- Valeria Moreno
Institutions
- Cleveland Clinic Florida (US)
Publication Details
- Journal
- Hematology Reports
- Published
- 2024-08-31
- DOI
- https://doi.org/10.3390/hematolrep16030054
- Citations
- 1
- Primary Topic
- Erythrocyte Function and Pathophysiology
- Type
- article
- Field-Weighted Citation Impact
- 0.33
Funders
- Cleveland Clinic